{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:27:50Z","timestamp":1788820070644,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hoc.2020.12.001","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T22:11:37Z","timestamp":1611612697000},"page":"159-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Overview of Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"35","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib1","first-page":"355","article-title":"Hematopathologic findings in the myeloproliferative disorders","volume":"22","author":"Dickstein","year":"1995","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.hoc.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5405","key":"10.1016\/j.hoc.2020.12.001_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","article-title":"Current trends in hematopoietic stem cell transplantation in Europe","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2020.12.001_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.001_bib9","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.hoc.2020.12.001_bib10","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.12.001_bib14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.001_bib15","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","article-title":"Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biology of blood and marrow transplantation","volume":"21","author":"Deeg","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.hoc.2020.12.001_bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s40265-017-0797-y","article-title":"Pharmacotherapy of myelofibrosis","volume":"77","author":"Tremblay","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2020.12.001_bib17","doi-asserted-by":"crossref","first-page":"100715","DOI":"10.1016\/j.blre.2020.100715","article-title":"Current and future therapies for myelofibrosis","volume":"42","author":"Asher","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2020.12.001_bib18","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib19","first-page":"13","article-title":"Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2008.07220.x","article-title":"Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera","volume":"142","author":"Cario","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0160-9327(00)01306-5","article-title":"Reading and writing the book of nature: Jan Swammerdam (1637\u20131680)","volume":"24","author":"Cobb","year":"2000","journal-title":"Endeavour"},{"issue":"3422","key":"10.1016\/j.hoc.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.132.3422.289","article-title":"Measuring the invisible world. The life and works of Antoni van Leeuwenhoek","volume":"132","author":"Hamarneh","year":"1960","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1365-2141.2001.02411.x","article-title":"Leukaemia: a brief historical review from ancient times to 1950","volume":"112","author":"Piller","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.12.001_bib25","unstructured":"Donne AF. De l'origine des globules du sang, de leur mode de formatton et de leur fin. Prov Med Surg J 1840;3(77):498\u20139."},{"key":"10.1016\/j.hoc.2020.12.001_bib26","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinburgh Med Sug J"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib27","first-page":"475","article-title":"Zwei f\u00e4lle von Leuk\u00e4mie mit eigenth\u00fcmlichem Blut-resp. Knochenmarksbefund","volume":"78","author":"Heuck","year":"1879","journal-title":"Archiv f\u00fcr pathologische Anatomie und Physiologie und f\u00fcr klinische Medicin"},{"key":"10.1016\/j.hoc.2020.12.001_bib28","first-page":"384","article-title":"Sur une forme sp\u00e9ciale de cyanose s\u2019 accompagnant d\u2019hyperglobulie excessive et persistante","volume":"44","author":"Vaquez","year":"1892","journal-title":"CR Soc Biol (Paris)"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000441-190308000-00001","article-title":"Chronic cyanosis, with polycyth\u00e6mia and enlarged spleen: a new clinical entity","volume":"126","author":"Osler","year":"1903","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.hoc.2020.12.001_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01891529","article-title":"Hemorrhagic thrombocythemia with a cascular, sclerotic spleen","volume":"293","author":"Epstein","year":"1934","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.12.001_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.12.001_bib35","unstructured":"Early approaches in the treatment of polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia vera and the myeloproliferative disorders. Philadelphia: WB Saunders Company; 1995. p. 147\u201353."},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib36","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib37","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib38","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"7037","key":"10.1016\/j.hoc.2020.12.001_bib39","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.hoc.2020.12.001_bib40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9464","key":"10.1016\/j.hoc.2020.12.001_bib41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-2796.2003.01126.x","article-title":"Life-threatening thrombotic complications of relative polycythaemia","volume":"253","author":"Biswas","year":"2003","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib43","first-page":"397","article-title":"Spurious polycythemia","volume":"12","author":"Weinreb","year":"1975","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hoc.2012.02.011","article-title":"Why does my patient have erythrocytosis?","volume":"26","author":"Kremyanskaya","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2141.2009.08069.x","article-title":"Advances in understanding the pathogenesis of primary familial and congenital polycythaemia","volume":"148","author":"Huang","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib46","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V89.6.2148","article-title":"Congenital polycythemia in Chuvashia","volume":"89","author":"Sergeyeva","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.20014","article-title":"Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency","volume":"75","author":"Hoyer","year":"2004","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1096\/fj.10-177378","article-title":"Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation","volume":"25","author":"Formenti","year":"2011","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2010.039545","article-title":"Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene","volume":"97","author":"Albiero","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib50","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2003-07-2535","article-title":"Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors","volume":"103","author":"Gordeuk","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2002-10-3246","article-title":"Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry","volume":"102","author":"Percy","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.12.001_bib52","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2020.12.001_bib53","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.001_bib54","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3324\/haematol.2018.213108","article-title":"Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values","volume":"104","author":"Silver","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.1991.tb00383.x","article-title":"Thrombocytosis in adults: analysis of 777 patients","volume":"229","author":"Santhosh-Kumar","year":"1991","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.hoc.2020.12.001_bib56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/asheducation-2007.1.363","article-title":"Thrombocytosis and thrombosis","author":"Vannucchi","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2141.1999.01710.x","article-title":"Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene","volume":"107","author":"Ghilardi","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2010.08500.x","article-title":"Advances in understanding the pathogenesis of familial thrombocythaemia","volume":"152","author":"Teofili","year":"2011","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2020.12.001_bib60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01013883","article-title":"Ultrastructure of chronic megakaryocytic-granulocytic myelosis","volume":"32","author":"Thiele","year":"1976","journal-title":"Blut"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib64","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.001_bib65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2020.12.001_bib66","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2020.12.001_bib67","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.12.001_bib68","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.12.001_bib69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2004.02.002","article-title":"Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders","volume":"19","author":"Kralovics","year":"2005","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.001_bib71","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.001_bib73","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.1989.tb04310.x","article-title":"Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts","volume":"72","author":"Kimura","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.12.001_bib74","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","author":"Ozono","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib75","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.12.001_bib76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.001_bib77","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis","volume":"200","author":"Tong","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib78","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2020.12.001_bib79","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2020.12.001_bib80","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.12.001_bib81","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib82","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib84","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.001_bib85","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2020.12.001_bib87","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib88","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.001_bib89","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.12.001_bib90","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.exphem.2006.07.004","article-title":"Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia","volume":"34","author":"Wang","year":"2006","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.hoc.2020.12.001_bib91","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-09-3977","article-title":"The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms","volume":"70","author":"Cho","year":"2010","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.001_bib92","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.001_bib93","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.001_bib94","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"Sekhar","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience","volume":"104","author":"Tremblay","year":"2019","journal-title":"Eur J Haematol"},{"issue":"21","key":"10.1016\/j.hoc.2020.12.001_bib96","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib97","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"van Genderen","year":"1996","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A\u00a0systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC cancer"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib100","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.12.001_bib101","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib103","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.hoc.2020.12.001_bib104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT Project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib105","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.001_bib106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.hoc.2020.12.001_bib107","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.12.001_bib108","article-title":"Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients","author":"Landtblom","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.001_bib109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.12.001_bib110","first-page":"1","article-title":"Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis","author":"Tremblay","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.hoc.2020.12.001_bib111","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.001_bib112","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.hoc.2020.12.001_bib113","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.12.001_bib114","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2020.12.001_bib115","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","article-title":"Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms","volume":"3","author":"Hong","year":"2019","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:05Z","timestamp":1760184905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0889858820301520"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.12.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}